Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VIR vs TAK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TAK Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

TAK Overall Winner 6-Pillar Tally: VIR 2 – 4 TAK Matrix Metrics: VIR 3 – 7 TAK

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Vir Biotechnology, Inc. (VIR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). VIR carries a Unified Composite Score of 41.6/100 (SELL) at $9.76 (4.3x Forward P/E, -70.2% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin).

  • Growth vs. Quality Trade-Off: TAK earns the overall head-to-head edge with a stronger Unified Composite Score (48.0/100 HOLD vs. VIR 41.6/100 SELL) and -0.02β · 22% Vol risk profile, whereas VIR leads top-line expansion (+19582.5% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VIR is currently in a Breakdown options structure phase (RSI 39.6); meanwhile TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 72.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VIR vs TAK
VIR NASDAQ
Vir Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.76
-2.01% 1D
Market Cap $2.1B
TTM Revenue $303M
Forward P/E 4.3x
Beta / 30D Vol 1.71β · 102% Vol
Unified Composite Score
41.6 / 100 SELL
Tech 20.0 Fund 46.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 39.6 · SMA20: $11.44 · SMA50: $11.11
TAK NYSE Head-to-Head Winner
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
TTM Revenue $25.7B
Forward P/E 12.7x
Beta / 30D Vol -0.02β · 22% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 43.0 Fund 44.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 72
RSI-14: 72.3 · SMA20: $20.71 · SMA50: $19.46

6-Pillar Scorecard Institutional Category Breakdown (VIR 2 – 4 TAK)

Columns: Metric · VIR · TAK
1. Valuation Multiples VIR
Forward P/E 4.3x 12.7x
Trailing P/E 4.3x N/M
PEG Ratio N/M 0.47x
EV / Revenue 6.4x 2.6x
2. Growth & Scale VIR
Revenue Growth (YoY) +19582.5% +6.7%
Earnings Growth (YoY) +58.5% -9.8%
TTM Revenue (USD) $303M $25.7B
Market Cap $2.1B $67.5B
3. Profitability & Quality TAK
Gross Margin -36.7% 64.8%
Operating Margin -70.2% 16.6%
Net Profit Margin -61.0% 0.9%
Return on Equity (ROE) -21.8% 0.6%
4. Balance Sheet & Cash Flow TAK
Cash Generation (TTM) -$142M $7.48B EBITDA
Cash Flow Margin -46.8% 29.1% EBITDA Mgn
Net Cash / Leverage $128M Net Cash $14.68 Book/Sh · 0.6% ROE
Dividend Yield None (0.00%) 2.92%
5. Options & Positioning TAK
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 69.6% (6th %ile) 22.4% (5th %ile)
Put/Call OI Skew 0.20x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat TAK
OpEx & R&D Intensity 33.5% of Rev ($101M) 48.2% of Rev ($12.4B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VIR (3) vs TAK (7)
Institutional Metric VIR TAK Criterion Row Edge
Market Capitalization
Scale
$2.1B $67.5B Larger Scale TAK
Trailing P/E Ratio
Valuation
4.3x N/M Lower Multiple VIR
Forward P/E Ratio
Valuation
4.3x 12.7x Lower Multiple VIR
Revenue Growth (YoY)
Growth
+19582.5% +6.7% Higher Growth VIR
Operating Margin (TTM)
Profitability
-70.2% 16.6% Higher Margin TAK
Net Profit Margin
Profitability
-61.0% 0.9% Higher Margin TAK
Return on Equity (ROE)
Capital Efficiency
-21.8% 0.6% Higher ROE TAK
52-Week Range Position
Momentum
49% ($5–$14) 97% ($14–$22) Stronger Trend TAK
Beta / 30D Volatility
Risk Regime
1.71β · 102% Vol -0.02β · 22% Vol Lower Realized Risk TAK
Unified Institutional Score
Composite Signal
41.6 / 100 (SELL) 48.0 / 100 (HOLD) Higher Composite TAK
Trailing 12M Revenue (USD)
Operating Scale
$303M $25.7B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-36.7% 64.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.4x EV/Rev 0.47x PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$142M ($128M Net Cash) $7.48B EBITDA ($14.68 Book/Sh · 0.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TAK +11.9 pp
VIR: -2.01% · TAK: +9.89%
3M Horizon TAK +16.9 pp
VIR: +2.85% · TAK: +19.75%
6M Horizon TAK +19.16 pp
VIR: +11.29% · TAK: +30.45%
1Y Horizon VIR +26.64 pp
VIR: +78.43% · TAK: +51.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VIR vs TAK. Trailing 12-month operating profitability (VIR -70.2% vs TAK 16.6%) and valuation multiples (VIR 4.3x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

VIR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$303M
Gross Margin-36.7%
Op. Margin-70.2%
ROE / Fwd P/E-21.8% · 4.3x
TAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.7B
Gross Margin64.8%
Op. Margin16.6%
ROE / Fwd P/E0.6% · 12.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VIR BREAKDOWN
5d in phase · OBV DISTRIBUTION
Current IV 69.6%
IV Percentile 6th %ile
Put/Call OI Skew 0.20x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact VIR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.4%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VIR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and -70.2% operating margin.
OpEx & R&D Reinvestment 33.5% of Rev ($101M)
90D Engineering Disclosures 0 Published
TAK Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($12.4B)
90D Engineering Disclosures 0 Published

Investor FAQ VIR vs TAK Key Questions & Quantitative Answers

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Vir Biotechnology, Inc. (VIR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). VIR carries a Unified Composite Score of 41.6/100 (SELL) at $9.76 (4.3x Forward P/E, -70.2% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin). Growth vs. Quality Trade-Off: TAK earns the overall head-to-head edge with a stronger Unified Composite Score (48.0/100 HOLD vs. VIR 41.6/100 SELL) and -0.02β · 22% Vol risk profile, whereas VIR leads top-line expansion (+19582.5% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VIR is currently in a Breakdown options structure phase (RSI 39.6); meanwhile TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 72.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VIR leads the Growth & Scale pillar: VIR posts +19582.5% YoY revenue growth and +58.5% YoY earnings growth on $303M TTM revenue (-36.7% gross margin, -70.2% operating margin), compared with TAK at +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin). On trailing 12-month operating scale, VIR generates $303M in USD-normalized revenue versus $25.7B for TAK. In operating R&D and SG&A reinvestment, VIR deploys 33.5% of Rev ($101M) (0 90-day corporate R&D disclosures) versus 48.2% of Rev ($12.4B) (0 disclosures) for TAK.

VIR screens cheaper on headline valuation multiples. VIR trades at 4.3x Forward P/E, 4.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-46.8% FCF margin), whereas TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIR (-21.8% ROE) versus TAK (0.6% ROE) capital efficiency.

In options market volatility and institutional positioning, VIR carries 69.6% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.20x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.71β · 102% Vol realized risk). By comparison, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.